<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836559</url>
  </required_header>
  <id_info>
    <org_study_id>CR108943</org_study_id>
    <secondary_id>2020-003698-24</secondary_id>
    <secondary_id>40411813EPY2001</secondary_id>
    <nct_id>NCT04836559</nct_id>
  </id_info>
  <brief_title>A Study to Investigate JNJ-40411813 in Combination With Levetiracetam in Epilepsy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects With Focal Onset Seizures With Suboptimal Response to Levetiracetam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive&#xD;
      JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in&#xD;
      participants with focal onset seizures who are receiving levetiracetam and up to 3 other&#xD;
      anti-epileptic drugs (AEDs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Baseline Monthly Seizure Count up to the end of the 12-week Double-blind Treatment Period</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Time to baseline monthly seizure count is defined, for each participant, as the number of days until the participants experienced the number of seizures equal to baseline monthly seizure count, up to the end of the 12-week double-blind treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Laboratory Results</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of participants with clinically significant changes in laboratory results related to hematology, serum chemistry, serology, and urinalysis will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of participants with clinically significant changes in vital signs including blood pressure and oral or tympanic temperature will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Results</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of participants with clinically significant changes in ECG results will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in the Double-blind Monthly Seizure Count</measure>
    <time_frame>Baseline, up to 12 weeks</time_frame>
    <description>Percent reduction in the double-blind monthly seizure count is defined as the double-blind monthly seizure count minus the baseline monthly seizure count, divided by the baseline monthly seizure count. The double-blind monthly seizure count is defined as the total number of observable focal onset seizures occurring during the 12-week double blind treatment period, multiplied by 28/xDB, where xDB is the number of days comprising the double-blind period. Observable seizures that will be counted during baseline and throughout the study include focal aware seizures with motor signs, focal impaired awareness seizures and focal to bilateral tonic-clonic seizures. Focal aware seizures without motor signs, myoclonic, or other generalized seizures will not be counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with no Seizures During Double-blind Period and who Achieve a More than (&gt;) 50 Percent (%) Reduction in Monthly Seizure Count Relative to Baseline Monthly Seizure Count</measure>
    <time_frame>Baseline, up to 12 weeks</time_frame>
    <description>Percentage of participants with no seizures during double-blind period and who achieve a &gt; 50% reduction in monthly seizure count relative to baseline monthly seizure count will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of JNJ-40411813</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 8, and 12</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-40411813 using a validated, specific, and sensitive liquid chromatography mass spectrometry/mass spectrometry (LC MS/MS) methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Levetiracetam</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 8, and 12</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of levetiracetam using a validated, specific, and sensitive LC MS/MS methods.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Focal Onset Seizures</condition>
  <arm_group>
    <arm_group_label>JNJ-40411813</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-40411813 twice a day (bid) up to 12 weeks. Up to 3 different doses (low, medium, high) of JNJ-40411813 will be administered in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo bid up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-40411813</intervention_name>
    <description>JNJ-40411813 will be administered orally.</description>
    <arm_group_label>JNJ-40411813</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m^2, inclusive&#xD;
             (BMI = weight/height^2). Minimum body weight should be 40-kilogram (kg)&#xD;
&#xD;
          -  Established diagnosis of focal epilepsy, for at least 1 year using the International&#xD;
             League Against Epilepsy (ILAE) criteria. Participants should not be enrolled if they&#xD;
             are known to have had fewer than 3 or more than 100 seizures in any monthly period in&#xD;
             the past 6 months. It is preferred that participants have experience in maintaining a&#xD;
             seizure e-diary&#xD;
&#xD;
          -  Must have had a neuroimaging procedure within 10 years, including a computed&#xD;
             tomography (CT) scan or magnetic resonance imaging (MRI), that excluded a progressive&#xD;
             neurologic disorder; these procedures may be performed within the 8-week baseline&#xD;
             period&#xD;
&#xD;
          -  Current treatment with at least 1 and up to 4 anti-epileptic drugs (AEDs) (including&#xD;
             levetiracetam), administered at stable dosage(s) for at least 1 month before&#xD;
             screening, and no new AEDs added for the previous 2 months; these AEDs must remain&#xD;
             unchanged throughout the pretreatment and double-blind treatment periods (with the&#xD;
             exception of dosage reductions of concomitant AEDs because of suspected elevated AED&#xD;
             levels or side effects)&#xD;
&#xD;
          -  Currently showing inadequate response to levetiracetam, administered at the&#xD;
             appropriate dosage(s) and for a sufficient treatment period, based on the judgment of&#xD;
             the investigator&#xD;
&#xD;
          -  Healthy based on clinical laboratory tests, physical examination, medical history,&#xD;
             vital signs, and 12-lead ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a generalized epileptic syndrome&#xD;
&#xD;
          -  Diagnosis of Lennox-Gastaut Syndrome&#xD;
&#xD;
          -  Currently experiencing seizures that cannot be counted accurately&#xD;
&#xD;
          -  History of any current or past nonepileptic seizures, including psychogenic seizures&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to placebo, JNJ-40411813 or its&#xD;
             excipients&#xD;
&#xD;
          -  Current treatment with vagus nerve stimulation, deep brain and cortical stimulation&#xD;
             for 1 year or less&#xD;
&#xD;
          -  Planned epilepsy surgery within the next 6 months or completed epilepsy surgery less&#xD;
             than (&lt;) 6 months ago&#xD;
&#xD;
          -  Current treatment with vigabatrin&#xD;
&#xD;
          -  History of malignancy within 5 years before screening (exceptions are squamous and&#xD;
             basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy,&#xD;
             which is considered cured with minimal risk of recurrence)&#xD;
&#xD;
          -  Current or past (within the past year) major psychotic disorder, such as&#xD;
             schizophrenia, bipolar disorder, or other psychotic conditions, recent (within the&#xD;
             past 6 months) interictal psychosis, and major depressive disorder (MDD) with&#xD;
             psychotic features&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tucson Neuroscience Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institution of Orlando, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension Medical Group</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Epilepsy and Sleep Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Mara - Bethel</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Alsterdorf gGmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonie Kork - Epilepsiezentrum</name>
      <address>
        <city>Kehl-Kork</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern der Ludwig-Maximilians-Universität</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Terapii SM</name>
      <address>
        <city>Katowice</city>
        <zip>40-571</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEURO-MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna</name>
      <address>
        <city>Katowice</city>
        <zip>40-686</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Lekarskie</name>
      <address>
        <city>Krakow</city>
        <zip>31-156</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-med Stec-Michalska sj</name>
      <address>
        <city>Ksawerów</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Best Solutions Sp. z o.o., Sp. K.</name>
      <address>
        <city>Lublin</city>
        <zip>20-078</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partnerska Lekarzy</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center sp. z o.o MEDIC-R s.k.</name>
      <address>
        <city>Poznań</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Hospital</name>
      <address>
        <city>Kazan</city>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Medical Center Your Health</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized clinical psychiatric hospital #1</name>
      <address>
        <city>Krasnodar</city>
        <zip>350007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical City Hospital #1</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nizny Novgorod clinical psychiatric hospital 1</name>
      <address>
        <city>Nizny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychoneurological Dispensary of Frunzensky District</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychoneurological dispensary 10</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St-Petersburg Bekhterev Psychoneurological Research Institute</name>
      <address>
        <city>St-Petersburg</city>
        <zip>192109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yaroslavl State Medical University</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medical Center of Private Enterprise Neuron</name>
      <address>
        <city>Kharkiv</city>
        <zip>61091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa)</name>
      <address>
        <city>Kyiv</city>
        <zip>02192</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mnpe of Lviv Regional Council 'Lviv Regional Clinical Psycho-Neurological Dispensary'</name>
      <address>
        <city>Lviv</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cnce of Lviv Regional Council 'Lviv Regional Clinical Hospital'</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'</name>
      <address>
        <city>Nove Settlement, Kropyvnytskyi</city>
        <zip>25491</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mnce 'Ternopil Regional Clinical Psychoneurology Hospital' of Trb</name>
      <address>
        <city>Ternopil</city>
        <zip>46027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Llc Diamed Medical Center</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cnpe 'Vinnytsia Regional Clinical Psycho-Neurological Hospital N.A. Ac. O.I. Yushchenko' of Vrc</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108943</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

